Lodo Therapeutics’ $970 Million Multi-Target Collaboration Agreement With Genentech

Cooley advised Lodo Therapeutics Corporation on its $969 million strategic drug discovery collaboration with Genentech, a member of the Roche Group.

Under the terms of the agreement, Genentech will utilize Lodo’s proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets. Lodo is eligible to receive research, development and commercialization milestone payments of up to $969 million and tiered royalties on sales of certain products.

Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected to reduce the time and cost of drug discovery.

Cooley advised with a team including Kenneth Krisko (Picture), Kristy Brady and Sonya Erickson.

Involved fees earner: Kenneth Krisko – Cooley LLP; Kristy Brady – Cooley LLP; Sonya Erickson – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Lodo Therapeutics Corp. ;

Author: Ambrogio Visconti